Daniel Katz, MD

Portrait
Surgical Director, VAMC Transplant Program
Associate Professor of Surgery - Transplantation and Hepatobiliary Surgery

Contact Information

Primary Office: GH SE400
Iowa City, IA 52242
319-356-1334

Education

BS, Biology, Fairleigh Dickinson University
MD, UMDNJ- Robert Wood Johnson Medical School

Resident, General Surgery, UMDNJ- Robert Wood Johnson Medical School
Fellow, Transplant Surgery, University of Pittsburgh Medical Center

Licensure and Certifications

Iowa Medical License
Board Certified - American Board of Surgery
National Board of Examiners

Research Summary

Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT- IM103008) and Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial- Extended Criteria Donors (BENEFIT-EXT IM103027) Bristol-Myers Squibb Belatacept (LEA29Y) represents a new class of immunosuppressive for use in renal transplantation. Belatacept is an immunomodulator that selectively inhibits costimulation of T-cells. The purpose of these two pivotal studies is to evaluate the effects of belatacept compared with cyclosporine on renal function and graft survival in kidney transplant recipients (IM103008) and in ECD kidney transplant recipients (IM103027). The primary objectives will be to evaluate the composite subject and graft survival by 12 months, the composite of measured GFR at month 12 or a decrease in measured GFR from month 3 to 12, and the incidence of acute rejection by month 12. Both studies are three-year phase III, multi center, randomized, partially-blinded, active controlled, parallel group study comparing three regimens: more intensive (MI) belatacept, less intensive (LI) belatacept, or cyclosporine. All will receive background therapy with basiliximab and maintenance with MMF and steroids. Belatacept is administered as a � hour infusion every two weeks for the first three months, then monthly until the end of the three year study. Belatacept Conversion Trial in Renal Transplantation (IM103010) Quintiles This trial is in the early start up phase and is currently pending. The trial will study the conversion of patients from a standard immunosuppressive regimen to a Belatacept based regimen. A 24-month, multicenter, randomized open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican � in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral � versus 1.44 g Myfortic � with standard dose Neoral � in de novo renal transplant recipients. Novartis Certican (everolimus, RAD001) is rapamycin derivative for renal transplant indications. The purpose of this study is to examine the impact of Certican with reduced Neoral dose on efficacy failure and renal function relative to Myfortic with standard dose of Neoral. The primary objective is to compare the composite efficacy failure rate (treated BPAR, graft loss, death, loss to follow up). Subjects will be randomized 1:1:1 to receive one of the two Certican doses with reduced dose Neoral or Myfortic with standard dose Neoral. Therapeutic drug monitoring will be performed to maintain the protocol required Neoral and Certican trough levels. All groups will receive background therapy with Simulect and steroids according to local practice. A retrospective study of en-block and split pediatric kidney transplant and outcomes at UIHC. Investigator initiated The purpose of this study is to collect and analyze the data from UIHC patient record for pediatric en- block and split pediatric kidney transplant under the donor age of 5 yrs. A retrospective data collection will be done for all the UIHC and affiliated sites for pediatric kidney transplant and analysis will be done for result, outcomes and efficiency of en-block and split pediatric kidney transplant from the donors under the age of 5 years. After analysis and result of these data we are hoping that we can increase procurement of kidneys for donation from the pediatric age group, increase the use of pediatric kidneys for organ transplantation, future clinical studies and ultimately increase renal graft survival rates, particularly those procured from children. There is recent evidence to suggest that en bloc kidneys have better long-term function than split pediatric kidneys. This observation may not be universal, but may be biased by center experience. We would like to extend our investigation to the national data set. Exploring the hypothesis that there is no center effect on pediatric kidney outcome comparing split and en bloc kidneys is relevant to the transplant community because acceptance or rejection of the hypothesis will have ramifications on organ allocation and usage. What is the effect hepatocellular tumor down staging prior to liver transplant? Investigator initiated In patients with cirrhosis, liver transplantation is indicated as a potentially curative therapy for patients with stage I and II hepatocellular carcinoma (HCC). Although initially controversial, multiple reports now demonstrate that five-year post transplant patient survival for cirrhotics with small tumors is similar to survival among patients undergoing transplant without cancer. Therefore, the transplant community as sanctioned by the United Network for Organ Sharing (UNOS) grants MELD (model for end stage liver disease) exception points to patients with small HCC in order to improve their status on the waiting list. However, patients with stage III and IV tumors have been found to have worse long term outcomes due to tumor